Blue Owl Capital

Eagle Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of injectable products, primarily targeting critical care, oncology, and orphan diseases. Utilizing the 505(b)(2) regulatory pathway, the company has successfully brought four products to market: Argatroban, Ryanodex, Belrapzo, and Bendeka. In addition to its approved products, Eagle Pharmaceuticals has several candidates in advanced stages of development, which are currently undergoing review by the Food and Drug Administration for potential approval.

Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain. The company aims to target pain at its source to provide effective, rapid-acting pain relief without the risk of addiction. Their lead program targets Nav1.8, a validated human pain target, leveraging internal ion channel expertise.

Capital on Tap specializes in providing a comprehensive small business credit card and spend management platform. It enables entrepreneurs to oversee employee cards, secure business funding, and earn cashback rewards on all purchases. With over a decade of focus on small businesses, Capital on Tap has been recognized for its rapid growth and has served over 200,000 customers who have spent more than $5 billion using their business credit cards.

Trillium Flow Technologies specializes in distributing valves, pumps, and aftermarket services for companies operating across various industries such as oil and gas, power generation, water treatment, and general manufacturing. The company offers durable products and comprehensive services from engineering to sustaining operations.

Databricks offers a unified data analytics platform that simplifies data integration, enables real-time experimentation, and facilitates robust deployment of production applications for developers and data scientists. Serving diverse industries worldwide, Databricks' platform supports collaborative data science, machine learning workflows, and integrates with various cloud services.

Windward Bio is a clinical-stage biopharmaceutical company dedicated to enhancing outcomes for patients with advanced immunological diseases, focusing on severe respiratory conditions. The company is advancing a fully human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 clinical trials. This antibody, administered subcutaneously, potently binds to the TSLP ligand, extending its half-life and silencing its effector functions. Windward Bio is also developing innovative bispecific programs for other immunological disorders, led by a team of experienced biopharmaceutical executives aiming to address significant unmet medical needs in this field.

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

Palvella Therapeutics is a biopharmaceutical company founded in 2015 and headquartered in Wayne, Pennsylvania. The company focuses on developing pathogenetically targeted therapies for serious and rare genetic skin diseases that lack approved treatments. Its lead candidate, QTORIN 3.9 % rapamycin anhydrous gel, is built on a patented QTORIN platform and is in late‑stage clinical development for two rare genodermatoses. Palvella’s approach emphasizes addressing the root cause of disease and delivering stable, room‑temperature formulations that penetrate the epidermis and dermis.

BITKRAFT Ventures is a global venture capital firm founded in 2015 by Jens Hilgers. It maintains a multi-city team with offices in Berlin, Los Angeles, San Francisco, New York, London, Madrid and Lisbon, and focuses on early-stage investments in videogames, esports and related immersive digital entertainment. Positioned as a global investment platform, it pursues opportunities across video gaming, immersive technology, interactive media, Web3 and AI, with activity spanning North America, Europe and Asia Pacific.

Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing treatments for patients undergoing organ or cellular transplantation and those with autoimmune and neurodegenerative diseases. Its lead compound, tegoprubart, is an anti-CD40L antibody targeting the CD40L pathway.

Founded in 2005, Interos Inc. specializes in supply chain risk management, offering a platform that aggregates and analyzes large datasets to identify relationships, patterns, and correlations. This enables clients to assess, monitor, and mitigate risks across their extended business ecosystems, including supply chains, partnerships, and alliances.

Founded in 2016, IPI Partners is a global investment platform specializing in data centers and technology-related real estate. The company acquires, develops, leases, and operates critical digital infrastructure assets, collaborating with major tech companies to serve the hyperscale and enterprise markets.

CloudPay is a provider of managed global payroll services tailored for multinational organizations, utilizing a single, unified SaaS platform. The company specializes in delivering end-to-end payroll solutions that ensure accurate and compliant payroll processing across over 130 countries and in more than twenty-five languages. By standardizing payroll functions across various geographies, CloudPay enhances operational efficiency, facilitates compliance, and offers greater visibility into payroll performance and costs. With over twenty years of industry experience and a client base of more than 2,500 multinational entities, CloudPay has earned recognition for its innovative technology and services, receiving multiple awards including accolades for Global Payroll Transformation and Payroll Software Product of the Year.

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell malignancies and autoimmune diseases. Its lead therapies include Umbralisib (PI3K delta and CK1 epsilon inhibitor) for NHL and CLL, Ublituximab (CD20-targeting antibody) for NHL, CLL, and MS, Cosibelimab (PD-L1 inhibitor), TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific antibody). The company has strategic alliances with several pharmaceutical companies and generates revenue primarily in the United States.

Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

TravelPerk is a SaaS platform that simplifies business travel management. It offers integrated booking, reporting, and support for flights, hotels, and car rentals, ensuring compliance with company policies.

AlphaSense is a market intelligence platform that helps research and business professionals discover, navigate, and monitor financial data and disclosures. The web-based platform collects data from filings, research, news, and other sources and makes it searchable through artificial intelligence and natural language processing, enabling users to search, set alerts, and analyze data points with accuracy. It serves a large enterprise base, including financial institutions and a majority of S&P 500 clients. Headquartered in New York, the company also operates offices in London, Helsinki, and Pune.

Dresser Utility Solutions specializes in engineered products for critical infrastructure within the global utility and industrial sectors. The company primarily serves the utility sector, focusing on the water and wastewater treatment segments. It manufactures a range of products including commercial and industrial natural gas meters, metering equipment, electronics, instrumentation, flow control devices, and overpressure protection solutions. Additionally, Dresser Utility Solutions addresses the needs of an ageing gas and water utility asset base, while responding to the increasing emphasis on environmental, social, and governance (ESG) considerations by providing innovative solutions for the water, gas, and electric markets worldwide.

Celcuity is a clinical-stage biotechnology company that discovers new cancer sub-types and therapeutic options using its proprietary CELsignia diagnostic platform. This platform analyzes living tumor cells to identify specific abnormal cellular processes driving cancer, enabling the development of targeted therapies for patients.

Founded in 2004, Linden Capital Partners is a Chicago-based private equity firm specializing in leveraged investments in middle market healthcare and life science companies across the United States.

Lycia Therapeutics operates as a biotechnology company focused on discovering and developing first-in-class therapeutics using its proprietary Lysosomal Targeting Chimeras (LYTACs) platform. This platform enables the degradation of extracellular and membrane-bound proteins associated with challenging-to-treat diseases like cancer and autoimmune disorders, aiming to provide effective treatments for patients.

Context Therapeutics is a clinical-stage biopharmaceutical company based in Philadelphia focused on developing medicines for hormone-responsive cancers, especially female, hormone-dependent tumors such as breast, ovarian, and endometrial cancers. Its lead program Apristor (Onapristone XR) is an investigational Phase 2 therapy for progesterone receptor–positive metastatic breast and ovarian cancers. The company is advancing CTX-030916, an oral antiprogestin candidate for uterine fibroids and endometriosis, and pursuing a discovery-stage program targeting Sigma1. It also has a preclinical program, CTIM-76, developing an anti-CLDN6 × anti-CD3 bispecific antibody to redirect T-cell–mediated killing toward Claudin 6–expressing cancer cells. Context Therapeutics aims to address hormone-driven solid tumors with a portfolio spanning clinical and preclinical assets.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Park Place Technologies specializes in third-party hardware maintenance and support services for IT data centers. It offers storage, server, and networking maintenance services, along with monitoring platforms like ParkView. Serving diverse sectors such as government, education, healthcare, cloud service providers, and IT companies globally.

Prima Capital Advisors LLC, located in Scarsdale, New York, is an investment advisory and asset management firm that specializes in commercial real estate debt investments. The company offers a range of services aimed at insurance companies, endowments, corporate and public pension plans, and sovereign wealth funds. Prima Capital focuses on generating income for its clients through investments in commercial mortgage whole loans, commercial mortgage-backed securities, and REIT bonds. By utilizing open-ended funds and separate accounts, the firm provides tailored investment strategies designed to meet the needs of its diverse clientele, ensuring a steady income stream while navigating the complexities of the real estate market.

Kuvare Asset Management (“KAM”) is Kuvare’s institutional investment management business.

Monotype is a global provider of type intellectual property and font technologies, offering a range of solutions that include custom type design services and enterprise software for visual content marketing. The company is dedicated to enhancing digital engagement and visual expression across various platforms, catering to designers, marketers, and engineers. Its products ensure a consistent user experience across digital devices, such as printers, copiers, and mobile devices, while also providing essential text experiences in numerous software applications and operating systems. Monotype licenses its design assets and technologies to creative professionals, consumer device manufacturers, and developers, enabling them to focus on creating impactful brand experiences. Headquartered in Woburn, Massachusetts, Monotype operates internationally in markets across the United States, Europe, the Middle East, Africa, and Japan.

Pyxis Oncology, established in 2019 in Boston, Massachusetts, is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company focuses on promoting the body's immune response to cancer by analyzing tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and tumor cell signaling pathways within cold tumors. Pyxis aims to create novel antibody-based immunotherapies to directly kill tumor cells and address underlying pathologies that enable cancer proliferation and immune evasion, with the goal of improving patient outcomes for difficult-to-treat cancers.

RLDatix is a software company that specializes in patient safety and quality improvement. Its cloud-based platform serves public and private healthcare organizations by enabling users to input, track, analyze, and report patient safety and incident data, helping clinicians and hospital administrators identify risks and implement targeted strategies to improve the delivery of safe and efficient care.

BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.

Vestwell provides a digital retirement platform that enables employers to establish retirement plans for their employees. The platform offers automated retirement investing options that comply with applicable rules and regulations for defined contribution plans, helping advisers administer client plans with enhanced compliance and automation.

XOMA Corporation is a biotechnology company that operates as a royalty aggregator, discovering and developing antibody-based therapies and licensing future economics or rights to pre-commercial candidates to pharmaceutical and biotechnology partners. It maintains a pipeline of monoclonal antibody programs and provides antibody discovery, optimization, and development technologies under collaboration with partners. Notable candidate programs include X213, an allosteric prolactin inhibitor; XMetA, an insulin receptor–activating antibody for long-acting reduction of hyperglycemia in Type 2 diabetes; an IL-2–based therapy for metastatic melanoma and renal cell carcinoma; and a PTH1R program addressing primary hyperparathyroidism and related conditions. The company collaborates with large pharma entities such as Novartis, Rezolute, and Takeda to advance clinical development. Founded in 1981, XOMA is headquartered in Emeryville, California, and operates with regional reach across the United States, Europe, Asia Pacific, and other markets.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Hayfin Capital Management is an independent investment firm headquartered in London that provides lending solutions to European middle-market companies and asset management services to institutional clients. Founded in 2009, it operates a European-focused platform with offices in London, Paris, Madrid, Frankfurt, Amsterdam, Luxembourg and Tel Aviv, and maintains a growing presence in the United States with New York. The firm concentrates on four credit strategies: Direct Lending, Special Opportunities, High-Yield Credit and Securitized Credit. It emphasizes value investing through rigorous analysis and disciplined investing, with a network-driven origination approach and specialized teams in healthcare, shipping and real estate to manage complex restructurings, workouts and liquidations. Hayfin aims to deliver risk-adjusted returns for investors and attract talented professionals across its markets.

Founded in 2017 through the merger of Misys and D+H, Finastra is a global leader in financial services software. It offers a wide range of solutions for retail banking, transaction banking, lending, treasury, capital markets, investment management, and enterprise risk domains. With a customer base comprising 48 of the world's top 50 banks, Finastra empowers clients to accelerate growth, optimize costs, mitigate risks, and adapt to evolving customer needs.

Wellfleet Credit Partners credit business Invetsment Firm .

6sense is a developer of a predictive intelligence platform that enhances revenue growth for organizations. The company utilizes artificial intelligence, big data, and machine learning to provide comprehensive visibility across the customer journey, from brand awareness to revenue generation. Its platform captures anonymous buying signals and buyer intent data, allowing sales, marketing, and customer success teams to target the right accounts effectively. By recommending optimal channels and messages, 6sense removes guesswork and inefficiencies from the sales process, leading to improved pipeline quality, accelerated sales velocity, and higher conversion rates. Through its innovative approach, 6sense aims to empower revenue teams to grow revenue predictably and efficiently.

Ascentium Group provides financial services.

Oak Street Real Estate Capital, LLC is a real estate investment firm based in Chicago, Illinois, that focuses on private equity investments in the office, industrial, and multifamily sectors. Established in 2011, the firm manages commingled funds and separate accounts for a diverse range of clients, including family offices, institutional investors, insurance companies, and trusts. Oak Street Real Estate Capital is recognized as a minority and women-owned business enterprise, emphasizing its commitment to diversity in the investment landscape. The firm typically seeks to make investments ranging from $10 million to $50 million, catering to the needs of its high net worth and institutional clientele.

ITM Isotopen Technologien München AG is a biotechnology and radiopharmaceutical company based in Garching, Germany, focusing on the development, manufacturing, and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for cancer treatment. Established in 2004, ITM has built a robust global supply network and accomplished GMP manufacturing capabilities. The company offers a range of products, including EndolucinBeta, a radiopharmaceutical precursor for targeted radionuclide therapy, as well as radionuclides like 225Ac and 213Bi. Additionally, ITM develops automated systems for synthesizing radiolabeled biomolecules and provides GMP radiolabeling services. With a growing portfolio of innovative treatments and partnerships, ITM aims to enhance patient outcomes and quality of life in oncology, specifically addressing conditions such as neuroendocrine cancers and bone metastases while minimizing side effects.

Crusoe AI Data Center is a joint venture of Crusoe, Blue Owl Capital and Primary Digital Infrastructure. The eight buildings are engineered for unparalleled scale, each capable of running up to 50,000 NVIDIA GB200 NVL72 units on a unified, integrated network fabric. This cutting-edge design pushes the boundaries of data center architecture, specifically for AI training and inference tasks. Additionally, the facilities will utilize advanced direct-to-chip liquid cooling systems that employ zero-water evaporation technology, continuously recirculating water in a closed loop to maximize efficiency and sustainability.

Crusoe AI Data Center is a joint venture of Crusoe, Blue Owl Capital and Primary Digital Infrastructure. The eight buildings are engineered for unparalleled scale, each capable of running up to 50,000 NVIDIA GB200 NVL72 units on a unified, integrated network fabric. This cutting-edge design pushes the boundaries of data center architecture, specifically for AI training and inference tasks. Additionally, the facilities will utilize advanced direct-to-chip liquid cooling systems that employ zero-water evaporation technology, continuously recirculating water in a closed loop to maximize efficiency and sustainability.

Consumer Cellular is a postpaid mobile virtual network operator based in Portland, Oregon, founded by John Marick and Greg Pryor in 1995. The company specializes in providing cellular services and devices tailored to users aged 50 and above, with a focus on no-contract cellphone plans. Consumer Cellular offers a range of products including mobile phones, smart phones, SIM cards, wireless home phone bases, and mobile hotspots. These are sold through retailers such as Target, the American Association of Retired Persons (AARP), and directly online. The company leases network capacity from AT&T and T-Mobile to provide its services.